{
    "paper_id": "PMC7169649",
    "metadata": {
        "title": "EMA: continue use of ACE inhibitors, sartans during COVID-19 pandemic",
        "authors": []
    },
    "body_text": [
        {
            "text": "\"It is important that patients do not interrupt their treatment with ACE inhibitors or ARBs and there is no need to switch to other medicines\",\n1 says the EMA.",
            "cite_spans": [],
            "section": "",
            "ref_spans": []
        },
        {
            "text": "The regulatory agency recently issued this advice following recent media reports and publications questioning whether some medicines (including ACE inhibitors or ARBs/sartans) \u2212 which are commonly used to treat patients with hypertension, heart failure or renal disease \u2212 could worsen the coronavirus disease (i.e. COVID-19) associated with the currently circulating strain (also known as SARS-CoV-2\n2).",
            "cite_spans": [],
            "section": "",
            "ref_spans": []
        },
        {
            "text": "The EMA noted that \"as the public health crisis rapidly extends across the globe\", scientists and epidemiologists around the world are carrying out research into how SARS-CoV-2 \"reproduces in the body, interacts with the immune system and causes disease, and whether ongoing treatment with medicines such as ACE-inhibitors and ARBs could impact the prognosis of COVID-19\".",
            "cite_spans": [],
            "section": "",
            "ref_spans": []
        },
        {
            "text": "Speculation that either ACE inhibitors or ARBs/sartans can worsen COVID-19 infections \"is not supported by clinical evidence\", noted the EMA, given that these medicines act via a different mechanism of action (i.e. the renin-angiotensin-aldosterone system [RAAS]). \"However, the interactions of the virus with the RAAS in the body are complex and not completely understood\", added the agency.",
            "cite_spans": [],
            "section": "",
            "ref_spans": []
        },
        {
            "text": "The EMA added that it is monitoring this safety concern closely and \"is helping to coordinate urgent ongoing research and is fully committed to keep the public up to date with any development in this field\".",
            "cite_spans": [],
            "section": "",
            "ref_spans": []
        },
        {
            "text": "Recently, the agency also announced that it was investigating reports claiming that NSAIDs (e.g. ibuprofen) could worsen COVID-19 symptoms, despite the fact that there is currently no scientific evidence to support this claim.\n3",
            "cite_spans": [],
            "section": "",
            "ref_spans": []
        }
    ],
    "ref_entries": {},
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        }
    }
}